Importance of immunodeficient mice for experimental and preclinical studies in oncology

Author: Mindar M.V.¹, Lukbanova E.A.², Kit S.O.³, A.E. Anisimov⁴, Egorov G.Yu.⁵, Volovik V.G.⁶

Abstract

In vivo tumor models created in various mouse strains play an important role in studies on antitumor therapies. An adequately selected model allows one to sufficiently assess the significance of the effect of the studied substance on molecular targets, its effect on the growth and viability of the tumor, and also to reveal a therapeutic window between the effectiveness of treatment and toxicity. An appropriately selected model allows an adequate assessment of the significance of the effect of the studied substance on molecular targets, the model’s effect on the growth and viability of the tumor, and also detection of a therapeutic window between the treatment effectiveness and toxicity. Xenografts of human tumors transplanted to immunodeficient mice are one of the most popular models for studying tumorigenesis and antitumor effects. Immunodeficiency of animal recipients is the prerequisite to prevent the rejection of tumor material from another biological species. A large number of different mouse strains have been developed, with varying severity of immune system defects and with various phenotypic and genotypic characteristics. The choice of an animal strain for a model creation depends on the research tasks. The success of an experiment directly depends on choosing the correct strain of experimental animals.

Key words

oncology, immunodeficient mice, tumor models, xenografts, patient-derived models, cancer models in vivo

References

Treshchalina E.M. Zhukova O.S., Gerasimova G.K., Andronova N.V., Garin A.M. Guidelines for the preclinical study of the antitumor activity of drugs. In: Preclinical Drug Research Guide. Part 1. Moscow: Grif i K, 2012. 642-657. [In Russian].
Gould S.E., Junttila M.R., de Sauvage F.J. Translational value of mouse models in oncology drug development. Nat. Med. 2015; 21 (5): 431-439. doi: 10.1038/nm.3853
Rangarajan A., Weinberg R.A. Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat. Rev. Cancer. 2003; 3 (12): 952-959. doi: 10.1038/nrc1235
Kelland L.R. “Of mice and men”: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur. J. Cancer. 2004; 40 (6): 827-836. doi: 10.1016/j.ejca.2003.11.028
Giovanella B.C., Fogh J. The nude mouse in cancer research. Adv. Cancer Res. 1985; 44: 69-120. doi: 10.1016/S0065-230X(08)60026-3
O'Connell M.P., Marchbank K., Webster M.R., Valiga A.A., Kaur A., Vultur A., Li L., Herlyn M., Villanueva J., Liu Q., Yin X., Widura S., Nelson J., Ruiz N., Camilli T.C., Indig F.E., Flaherty K.T., Wargo J.A., Frederick D.T., Cooper Z.A., Nair S., Amaravadi R.K., Schuchter L.M., Karakousis G.C., Xu W., Xu X., Weeraratna A.T. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov. 2013; 3 (12): 1378-1393. doi: 10.1158/2159-8290.CD-13-0005
Szadvari I., Krizanova O., Babula P. Athymic nude mice as an experimental model for cancer treatment. Physiol. Res. 2016; 65 (4): 441-453. doi: 10.33549/physiolres.933526
Holub M. The nude mouse. ILAR J. 1992; 34 (1-2): 1-3. doi: 10.1093/ilar.34.1-2.1
Hong H.K., Noveroske J.K., Headon D.J., Liu T., Sy M.S., Justice M.J., Chakravarti A. The winged helix/forkhead transcription factor Foxq1 regulates differentiation of hair in satin mice. Genesis. 2001; 29 (4): 163-171. doi: 10.1002/gene.1020
Bankert R.B., Egilmez N.K., Hess S.D. Human–SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol. 2001; 22 (7): 386-393. doi: 10.1016/s1471-4906(01)01943-3
Fugmann S.D. RAG1 and RAG2 in V (D) J recombination and transposition. Immunol. Res. 2001; 23 (1): 23-39. doi: 10.1385/IR:23:1:23
Mekada K., Abe K., Murakami A., Nakamura S., Nakata H., Moriwaki K., Obata Y., Yoshiki A. Genetic differences among C57BL/6 substrains. Exp. Anim. 2009; 58 (2): 141-149. doi: 10.1538/expanim.58.141
Vladutiu A.O. The severe combined immunodeficient (SCID) mouse as a model for the study of autoimmune diseases. Clin. Exp. Immunol. 1993; 93 (1): 1-8. doi: 10.1111/j.1365-2249.1993.tb06488.x
Lee J.H., Park J.H., Nam T.W., Seo S.M., Kim J.Y., Lee H.K., Han J.H., Park S.Y., Choi Y.K., Lee H.W. Differences between immunodeficient mice generated by classical gene targeting and CRISPR/Cas9-mediated gene knockout. Transgenic Res. 2018; 27 (3): 1-11. doi: 10.1007/s11248-018-0069-y
Fischer A. Severe combined immunodeficiencies (SCID). Clin. Exp. Immunol. 2000; 122 (2): 143-149. doi: 10.1046/j.1365-2249.2000.01359.x
Jung J., Seol H.S., Chang S. The generation and application of patient-derived xenograft model for cancer research. Cancer Res. Treat. 2018; 50 (1): 1. doi: 10.4143/crt.2017.307
De Camargo M.M., Nahum L.A. Adapting to a changing world: RAG genomics and evolution. Hum. Genomics. 2005; 2 (2): 132-137. doi: 10.1186/1479-7364-2-2-132
Mehalow A.K., Kameya S., Smith R.S., Hawes N.L., Denegre J.M., Young J.A., Bechtold L., Haider N.B., Tepass U., Heckenlively J.R., Chang B., Naggert J.K., Nishina P.M. CRB1 is essential for external limiting membrane integrity and photoreceptor morphogenesis in the mammalian retina. Hum. Mol. Genet. 2003; 12 (17): 2179-2189. doi: 10.1093/hmg/ddg232
Huang T.T., Naeemuddin M., Elchuri S., Yamaguchi M., Kozy H.M., Carlson E.J., Epstein C.J. Genetic modifiers of the phenotype of mice deficient in mitochondrial superoxide dismutase. Hum. Mol. Genet. 2006; 15 (7): 1187-1194. doi: 10.1093/hmg/ddl034
Leiter E.H. The NOD mouse: a model for analyzing the interplay between heredity and environment in development of autoimmune disease. ILAR J. 1993; 35 (1): 4-14. doi: 10.1093/ilar.35.1.4
Watanabe Y., Takahashi T., Okajima A., Shiokawa M., Ishii N., Katano I., Ito R, Ito M., Minegishi M., Minegishi N., Tsuchiya S., Sugamura K. The analysis of the functions of human B and T cells in humanized NOD/shi-scid/γcnull (NOG) mice (hu-HSC NOG mice). Int. Immunol. 2009; 21 (7): 843-858. doi: 10.1093/intimm/dxp050
Bente D.A., Melkus M.W., Garcia J.V., Rico-Hesse R. Dengue fever in humanized NOD/SCID mice. J. Virol. 2005; 79 (21): 13797-13799. doi: 10.1128/JVI.79.21.13797-13799.2005
Anderson M.S., Bluestone J.A. The NOD mouse: a model of immune dysregulation. Annu. Rev. Immunol. 2005; 23: 447-485. doi: 10.1146/annurev.immunol.23.021704.115643
Shultz L.D., Goodwin N., Ishikawa F., Hosur V., Lyons B.L., Greiner D.L. Human cancer growth and therapy in NOD/SCID/IL2Rγnull (NSG) mice. Cold Spring Harb. Protoc. 2014; 2014 (7): 694-708. doi: 10.1101/pdb.top073585
Puchalapalli M., Zeng X., Mu L., Anderson A., Glickman L.H., Zhang M., Sayyad M.R., Mosticone Wangensteen S., Clevenger C.V., Koblinski J.E. NSG mice provide a better spontaneous model of breast cancer metastasis than athymic (nude) mice. PLoS One. 2016; 11 (9): e0163521. doi: 10.1371/journal.pone.0163521
Sweeney C.L., Choi U., Liu C., Koontz S., Ha S.K., Malech H.L. CRISPR-mediated knockout of Cybb in NSG mice establishes a model of chronic granulomatous disease for human stem-cell gene therapy transplants. Hum. Gene Ther. 2017; 28 (7): 565-575. doi: 10.1089/hum.2017.005
Ohbo K., Suda T., Hashiyama M., Mantani A., Ikebe M., Miyakawa K., Moriyama M., Nakamura M., Katsuki M., Takahashi K., Yamamura K., Sugamura K. Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor gamma chain. Blood. 1996; 87 (3): 956-967.
Pearson T., Greiner D.L., Shultz L.D. Creation of “humanized” mice to study human immunity. Curr. Protoc. Immunol. 2008; 81 (1): 15-21. doi: 10.1002/0471142735.im1521s81
Inoue M., Senju S., Hirata S., Irie A., Baba H., Nishimura Y. An in vivo model of priming of antigen-specific human CTL by Mo-DC in NOD/Shi-scid IL2rγnull (NOG) mice. Immunology Lett. 2009; 126 (1-2): 67-72. doi: 10.1016/j.imlet.2009.08.001
Yasuda M., Ogura T., Goto T., Yagoto M., Kamai Y., Shimomura C., Hayashimoto N., Kiyokawa Y., Shinohara H., Takahashi R., Kawai K. Incidence of spontaneous lymphomas in non-experimental NOD/Shi-scid, IL-2Rγnull (NOG) mice. Exp. Anim. 2017; 66 (4): 425-435. doi: 10.1538/expanim.17-0034
Holen I., Speirs V., Morrissey B., Blyth K. In vivo models in breast cancer research: progress, challenges and future directions. Dis. Model Mech. 2017; 10 (4): 359-371. doi: 10.1242/dmm.028274
Lallo A., Frese K.K., Morrow C.J., Sloane R., Gulati S., Schenk M.W., Trapani F., Simms N., Galvin M., Brown S., Hodgkinson C.L., Priest L., Hughes A., Lai Z., Cadogan E., Khandelwal G., Simpson K.L., Miller C., Blackhall F., O'Connor M.J., Dive C. The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer. Clinical Cancer Research. 2018; 24 (20): 5153-5164. doi: 10.1158/1078-0432.CCR-17-2805
Zhang S., Zheng C., Zhu W., Xiong P., Zhou D., Huang C., Zheng D. A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors. Theranostics. 2019; 9 (18): 5412-5423. doi: 10.7150/thno.33598
Lowery C.D., Dowless M., Renschler M., Blosser W., VanWye A. B., Stephens J. R., Iversen P.W., Lin A.B., Beckmann R.P., Krytska K., Cole K.A., Maris J.M., Hawkins D.S., Rubin B.P., Kurmasheva R.T., Houghton P.J., Gorlick R., Kolb E.A., Kang M.H., Reynolds C.P., Erickson S.W., Teicher B.A., Smith M.A., Stancato L.F. Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models. Clin. Cancer Res. 2019; 25 (7): 2278-2289. doi: 10.1158/1078-0432.CCR-18-2728
Dowless M., Lowery C. D., Shackleford T., Renschler M., Stephens J., Flack R., Blosser W.^., Gupta S., Stewart J., Webster Y., Dempsey J., VanWye A.B.,, Ebert P., Iversen P., Olsen J.B., Gong X., Buchanan S., Houghton P., Stancato L. Abemaciclib is active in preclinical models of ewing sarcoma via multipronged regulation of cell cycle, DNA methylation, and interferon pathway signaling. Clin. Cancer Res. 2018; 24 (23): 6028-6039. doi: 10.1158/1078-0432.CCR-18-1256
Xie J., Lin Y. Patient-derived xenograft models for personalized medicine in colorectal cancer. Clin. Exp. Med. 2020; 20 (4): 167–172. doi: 10.1007/s10238-020-00609-4
Klinghammer K., Walther W., Hoffmann J. Choosing wisely–Preclinical test models in the era of precision medicine. Cancer treatment reviews. 2017; 55: 36-45. doi: 10.1016/j.ctrv.2017.02.009
Kit S.O., Maksimov A.Yu., Goncharova A.S., Kolesnikov E.N., Sanamyants S.V., Katsieva TB, Myagkov R.E., Lukbanova E.A., Karnaukhov N.S., Tkachev S.Yu., Protasova T.P., Zaikina E.V., Volkova A.V., Khodakova D.V., Mindar M.V. Growth characteristics of patient-like subcutaneous and orthotopic xenografts of human cardioesophageal cancer in immunodeficient mice. Sovremennye problemy nauki i obrazovaniya = Modern problems of science and education. 2020; (2). URL https://science-education.ru/ru/article/view?id=29573 [In Russian].
Chen Q., Wei T., Wang J., Zhang Q., Li J., Zhang J., Ni L., Wang Y., Bai X., Liang T. Patient-derived xenograft model engraftment predicts poor prognosis after surgery in patients with pancreatic cancer. Pancreatology. 2020; 20(3): 485-492. doi: 10.1016/j.pan.2020.02.008
Okano M., Oshi M., Butash A., Okano I., Saito K., Kawaguchi T., Nagahashi M., Kono K., Ohtake T., Takabe K. Orthotopic implantation achieves better engraftment and faster growth than subcutaneous implantation in breast cancer patient-derived xenografts. J. Mammary Gland Biol. Neoplasia. 2020; 25 (1): 27-36. doi: 10.1007/s10911-020-09442-7
Wu P., Xu R., Chen X., Zhao Y., Tan D., Zhao Y., Qin W., Zhang C., Ge X., Shi C. Establishment and characterization of patient-derived xenografts for hormone-naïve and castrate-resistant prostate cancers to improve treatment modality evaluation. Aging (Albany NY). 2020; 12 (4): 3848-3861. doi: 10.18632/aging.102854
Wang M., Yao L.C., Cheng M., Cai D., Martinek J., Pan C.X., Shi W., Ma A.H., De Vere White R.W., Airhart S., Liu E.T., Banchereau J., Brehm M.A., Greiner D.L., Shultz L.D., Palucka K., Keck J.G. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J. 2018; 32 (3): 1537-1549. doi: 10.1096/fj.201700740R
Kuryk L., Møller A.S.W., Jaderberg M. Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model. Oncoimmunology. 2019; 8 (2): e1532763. doi: 10.1080/2162402X.2018.1532763
Zhou Z.F., Peng F., Li J.Y., Ye Y.B. Intratumoral IL-12 gene therapy inhibits tumor growth in A HCC-Hu-PBL-NOD/SCID murine model. Onco Targets Ther. 2019; 12: 7773-7784. doi: 10.2147/OTT.S222097
Belizário J.E. Immunodeficient mouse models: an overview. Open Immunol. J. 2009; 2 (1): 79-85. doi: 10.2174/1874226200902010079
Georges L.M.C., De Wever O., Galván J.A., Dawson H., Lugli A., Demetter P., Zlobec I. Cell line derived xenograft mouse models are a suitable in vivo model for studying tumor budding in colorectal cancer. Front. Med. 2019; 6: 139. doi: 10.3389/fmed.2019.00139
Marques da Costa M.E., Daudigeos‐Dubus E., Gomez‐Brouchet A., Bawa O., Rouffiac V., Serra M. Scotlandi K., Santos C., Geoerge B., Gaspar N. Establishment and characterization of in vivo orthotopic bioluminescent xenograft models from human osteosarcoma cell lines in Swiss nude and NSG mice. Cancer Med. 2018; 7 (3): 665-676. doi: 10.1002/cam4.1346
Feng B., Zhu Y., Sun C., Su Z., Tang L., Li C., Zheng G. Basil polysaccharide inhibits hypoxia-induced hepatocellular carcinoma metastasis and progression through suppression of HIF-1α-mediated epithelial-mesenchymal transition. Int. J. Biol. Macromol. 2019; 137: 32-44. doi: 10.1016/j.ijbiomac.2019.06.189
Vishnoi M., Liu N.H., Yin W., Boral D., Scamardo A., Hong D., Marchetti D. The identification of a TNBC liver metastasis gene signature by sequential CTC‐xenograft modeling. Mol. Oncol. 2019; 13 (9): 1913-1926. doi: 10.1002/1878-0261.12533
Blomme A., Van Simaeys G., Doumont G., Costanza B., Bellier J., Otaka Y., Sherer F., Lovinfosse P., Boutry S., Palacios A.P., De Pauw E., Hirano T., Yokobori T., Hustinx R., Bellahcène A., Delvenne P., Detry O., Goldman S., Nishiyama M., Castronovo V., Turtoi A. Murine stroma adopts a human-like metabolic phenotype in the PDX model of colorectal cancer and liver metastases. Oncogene. 2018; 37 (9): 1237-1250. doi: 10.1038/s41388-017-0018-x
Bertin H., Guilho R., Brion R., Amiaud J., Battaglia S., Moreau A., Gomez A.B., Longis J., Piot B., Heymann D., Corre P., Rédini F. Jaw osteosarcoma models in mice: first description. J. Transl. Med. 2019; 17 (1): 56. doi: 10.1186/s12967-019-1807-5
Wang Z.M., Zhang S L., Yang H., Zhuang R Y., Guo X., Tong H X., Zhang Y., Lu W.Q., Zhou Y H. Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma. Cancer Med. 2020. doi: 10.1002/cam4.2941
Lin S., Huang G., Cheng L., Li Z., Xiao Y., Deng Q., Jiang Y., Li B., Lin S., Wang S., Wu Q., Yao H., Cao S., Li Y., Liu P., Wei W., Pei D., Yao Y., Wen Z., Zhang X., Wu Y., Zhang Z., Cui S., Sun X., Qian X., Li P. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. MAbs. 2018; 10 (8): 1301-1311. doi: 10.1080/19420862.2018.1518948
Choi B., Lee J.S., Kim S.J., Hong D., Park J.B., Lee K.Y. Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma. Cancer Lett. 2020; 478: 56-69. doi: 10.1016/j.canlet.2020.02.042
Landgraf M., Lahr C.A., Kaur I., Shafiee A., Sanchez-Herrero A., Janowicz P.W., Ravichandran A., Howard C.B., Cifuentes-Rius A., McGovern J.A., Voelcker N.H., Hutmacher D.W. Targeted camptothecin delivery via silicon nanoparticles reduces breast cancer metastasis. Biomaterials. 2020; 240: 119791. doi: 10.1016/j.biomaterials.2020.119791
Kähkönen T.E., Suominen M.I., Mäki-Jouppila J.H., Halleen J.M., Tanaka A., Seiler M., Bernoulli J. Human immune system increases breast cancer-induced osteoblastic bone growth in a humanized mouse model without affecting normal bone. J. Immunol. Res. 2019; 2019. doi: 10.1155/2019/4260987

About Authors (Correspondence):

Mindar M.V., e-mail: m.v.mindar@gmail.com

Full Text

snmzh_3-2020_mindar_i_dr.pdf

Received: 30/06/2020

Accepted: 30/06/2020